TAE684 (NVP-TAE684)

TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR.

Price Stock Quantity  
USD 269 In stock
USD 160 In stock
USD 290 In stock
USD 770 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

TAE684 (NVP-TAE684) Chemical Structure

TAE684 (NVP-TAE684) Chemical Structure
Molecular Weight: 614.2

Validation & Quality Control

Customer Product Validation(4)

Quality Control & MSDS

Related Compound Libraries

ALK Inhibitors with Unique Features

  • Non-specific ALK Inhibitor

    GSK1838705A IGF-1R, IC50=2.0 nM; IR, IC50=1.6 nM, ALK, IC50=0.5 nM.

  • Most Potent ALK Inhibitor

    Ceritinib (LDK378) ALK, IC50=0.2 nM.

  • FDA-approved ALK Inhibitor

    Crizotinib (PF-02341066) Approved by FDA for non-small cell lung carcinoma (NSCLC).

  • Newest ALK Inhibitor

    ASP3026 Novel and selective inhibitor for ALK with IC50 of 3.5 nM.

Product Information

  • Compare ALK Inhibitors
    Compare ALK Products
  • Research Area
  • TAE684 (NVP-TAE684) Mechanism

Product Description

Biological Activity

Description TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR.
Targets ALK [1]
(Cell-free assay)
IC50 3 nM
In vitro TAE684 does not exhibit significant cross-reactivity against other kinases. TAE684 potently inhibits the proliferation of Ba/F3 NPM-ALK cells with IC50 of 3 nM, without affecting the survival of Ba/F3 cells even at 1 μM. TAE684 also inhibits proliferation of NPM-ALK-expressing human ALCL cell lines including Karpas-299 and SU-DHL-1 with IC50 of 2–5 nM. Molecular modeling reveals that L258 may be one of the major kinase-selectivity determinants for TAE684. TAE684 treatment results in a rapid and sustained inhibition of phosphorylation of NPM-ALK. TAE684 induces apoptosis and G1 phase arrest in NPM-ALK-expressing Ba/F3 cells and ALCL patient cell lines. [1] TAE684 markedly overcomes Crizotinib-resistance in H3122 CR cells, harboring the fusion oncogene EML4-ALK, decreasing cell growth, suppressing ALK phosphorylation and inducing apoptosis.[2] Neurite outgrowth induced by expression of the mALK R1279Q mutant could be completely inhibited by TAE684 at 30 nM. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
SCC-3MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPSTXdKSzVyPUCuNFAxODZyMzFOwG0>NHTtUI1USU6JRWK=
SF539NIjqZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTBwMECwOVY1KM7:TR?=NWXmUFZbW0GQR1XS
DELM3zzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXjJR|UxRTBwMECwPVI4KM7:TR?=NFvIVHZUSU6JRWK=
NB1NV7YO2RRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWT2SGJLUUN3ME2wMlAxOTZ{IN88US=>NGO2WoRUSU6JRWK=
SRNH3YfolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTBwMECyO|ch|ryPMWjTRW5ITVJ?
KARPAS-299M1fGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmDtTWM2OD1yLkCyN|g1KM7:TR?=NYfIdmQ5W0GQR1XS
MHH-CALL-2NF;odYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jqNWlEPTB;MD6wNlk2OiEQvF2=MV3TRW5ITVJ?
SU-DHL-1M1jzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjkW5d5UUN3ME2wMlA1QDZ3IN88US=>MXfTRW5ITVJ?
A4-FukNWrBdnY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTBwMEW1OlUh|ryPMYPTRW5ITVJ?
EW-1M2jO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYTPSVhEUUN3ME2wMlExOjV4IN88US=>NELBfZhUSU6JRWK=
NOS-1MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LYdWlEPTB;MD6xNFI6PCEQvF2=M{XoPXNCVkeHUh?=
EW-16MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEfQbFRKSzVyPUCuNVA2PjhizszNNH7SUlhUSU6JRWK=
TE-11MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHG3WXdKSzVyPUCuNVYxQTZizszNM17jbXNCVkeHUh?=
SW982MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLaTWM2OD1yLkG2OFc5KM7:TR?=NHrB[JlUSU6JRWK=
LAN-6NIS0enBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH;wRlBKSzVyPUCuNVc1PDNizszNMVvTRW5ITVJ?
MZ1-PCMnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH\HUYFKSzVyPUCuNVc5OzVizszNM2DKeHNCVkeHUh?=
KS-1NVnrZWN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIL4UGVKSzVyPUCuNVk{PDNizszNMmnNV2FPT0WU
PSN1M3T1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\UTWM2OD1yLkG5OlMyKM7:TR?=M4\HO3NCVkeHUh?=
LC-2-adNFXm[G1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFq0b2pKSzVyPUCuNVk3QTJizszNMWfTRW5ITVJ?
COLO-320-HSRMm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4n4eWlEPTB;MD6xPVc4PiEQvF2=NX\nTWpSW0GQR1XS
OPM-2NVKyUFdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnS5TWM2OD1yLkKyOlY6KM7:TR?=M3fFRnNCVkeHUh?=
SK-NEP-1MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkmzTWM2OD1yLkKzOVI1KM7:TR?=NVr0OolNW0GQR1XS
ALL-POM{fPcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDrPHRnUUN3ME2wMlI1PTJ2IN88US=>M{nwTHNCVkeHUh?=
CMKM3XFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjwTWM2OD1yLkK1OVMh|ryPMUPTRW5ITVJ?
NCI-H1648NWTCbopRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTBwMke4OVUh|ryPMUfTRW5ITVJ?
SIG-M5MkfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUOzT21pUUN3ME2wMlI6OTV7IN88US=>M4C2cHNCVkeHUh?=
TGBC24TKBM3Pme2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MofoTWM2OD1yLkOwNlE5KM7:TR?=NV3NPGY4W0GQR1XS
DOHH-2M3\4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nx[WlEPTB;MD6zNVIxPCEQvF2=Ml7PV2FPT0WU
NB69M2PLdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4Hyd2lEPTB;MD6zNVc5PyEQvF2=NH;6WJBUSU6JRWK=
MFH-inoMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlH0TWM2OD1yLkOyOVI{KM7:TR?=NG\DblZUSU6JRWK=
KP-N-RT-BM-1NXrLfVlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkCwTWM2OD1yLkOzNVI{KM7:TR?=M{noN3NCVkeHUh?=
MONO-MAC-6Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn7VTWM2OD1yLkOzNlkyKM7:TR?=M13NfXNCVkeHUh?=
ATN-1NUXjZ5h{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHHmR4JKSzVyPUCuN|M{ODNizszNNV;5bpc4W0GQR1XS
NTERA-S-cl-D1M{TrUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXjJR|UxRTBwM{OzPVYh|ryPNU\R[2F{W0GQR1XS
L-540MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3v0cmlEPTB;MD6zOlk5QCEQvF2=NVTGTY5wW0GQR1XS
GB-1NYLrNFNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTBwM{i4Olch|ryPMV7TRW5ITVJ?
MV-4-11NHPyZYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVvMb5l{UUN3ME2wMlM6PDR4IN88US=>M1H6bHNCVkeHUh?=
KG-1NYTBZ|gyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTBwM{m1OlEh|ryPMl31V2FPT0WU
OVCAR-4MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnETWM2OD1yLkSwOVY6KM7:TR?=MkXVV2FPT0WU
NEC8M1S4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1vu[2lEPTB;MD60NVI6OiEQvF2=NITwTVVUSU6JRWK=
SK-MM-2NIjDSYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVrhdFVzUUN3ME2wMlQyPjB7IN88US=>NXfwSXZwW0GQR1XS
TE-8NF[zSoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkP6TWM2OD1yLkSyPFgh|ryPMXvTRW5ITVJ?
697MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlrETWM2OD1yLkSzNlE2KM7:TR?=MXvTRW5ITVJ?
NB14MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFi2NZVKSzVyPUCuOFM5OjZizszNNFS4c45USU6JRWK=
GDM-1NUPvPG5IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2fmbWlEPTB;MD60O|EyPiEQvF2=MkjhV2FPT0WU
HUTU-80NF\RbXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MknwTWM2OD1yLkS3N|c2KM7:TR?=Ml[xV2FPT0WU
HL-60MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml[zTWM2OD1yLkS4NVQzKM7:TR?=Moi4V2FPT0WU
OCI-AML2NGjnd2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlmxTWM2OD1yLkS4N|I5KM7:TR?=NFL5b25USU6JRWK=
ML-2MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnrYTWM2OD1yLkS5NFMyKM7:TR?=M4DTcXNCVkeHUh?=
ES4MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTBwNEmxNFkh|ryPNFHZVW1USU6JRWK=
NCI-H747MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTHRWRrUUN3ME2wMlQ6QDlizszNNX3Pb3BEW0GQR1XS
RL95-2MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PscWlEPTB;MD61NFEyOiEQvF2=NEfGcmRUSU6JRWK=
TE-15NHrxOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3rXeWlEPTB;MD61NVEzPCEQvF2=MXHTRW5ITVJ?
TE-12MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlTlTWM2OD1yLkWzN|Q6KM7:TR?=NIfWcmhUSU6JRWK=
LB1047-RCCMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXqbXZKSzVyPUCuOVQ2PDlizszNNHnJd2RUSU6JRWK=
LB831-BLCMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1HMR2lEPTB;MD61OVAzOyEQvF2=MULTRW5ITVJ?
NCI-H1355M2C2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTBwNUWxPFQh|ryPM4TrXnNCVkeHUh?=
CTV-1M2HndGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MULJR|UxRTBwNUW2NlQh|ryPMVfTRW5ITVJ?
RXF393NXX5RohCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIW5NXZKSzVyPUCuOVU4QTRizszNNXjPOnBvW0GQR1XS
SW872NFGxN3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIPGcppKSzVyPUCuOVY4OjRizszNNFvkSppUSU6JRWK=
MPP-89M{Pme2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDPV5dKSzVyPUCuOVc5QDRizszNNHTXVFVUSU6JRWK=
RPMI-8226NVW4W4Q1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTBwNkO1NlYh|ryPNI\RSJdUSU6JRWK=
LS-1034MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mme2TWM2OD1yLk[zOVgh|ryPM3j3e3NCVkeHUh?=
SJSA-1NHTDNVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTMTWM2OD1yLk[zO|I2KM7:TR?=MoLWV2FPT0WU
HOP-62NVe2b4pFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;rSmlEPTB;MD62OVA{OyEQvF2=NUHCN|FCW0GQR1XS
KGNMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlmzTWM2OD1yLk[2NVY5KM7:TR?=NV3Rb|hqW0GQR1XS
D-336MGMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTBwNk[xOlkh|ryPNXXOemI5W0GQR1XS
LS-411NM1PRbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWG5WmRlUUN3ME2wMlY4PDZ{IN88US=>NHf0NGVUSU6JRWK=
TE-1NGPOW|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3lNnpiUUN3ME2wMlY6ODd2IN88US=>M{S5TnNCVkeHUh?=
LB996-RCCNE\mNXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV34cYVnUUN3ME2wMlY6Ozh7IN88US=>MnXHV2FPT0WU
TE-10M3TLOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTBwN{G0PVYh|ryPMV\TRW5ITVJ?
NCI-SNU-16MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVe2[WZtUUN3ME2wMlczPjZ2IN88US=>NV7XWW51W0GQR1XS
ES8NXrITpNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEDObGJKSzVyPUCuO|Q6PzVizszNMWPTRW5ITVJ?
COLO-800NXXMfXoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;GdlhKUUN3ME2wMlc3Pjl3IN88US=>NYG1d41ZW0GQR1XS
ES6MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEfO[YdKSzVyPUCuO|c2PTlizszNM2Pnd3NCVkeHUh?=
L-363NFnVOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnGco5KSzVyPUCuPFI{PzVizszNM4i1SnNCVkeHUh?=
NMC-G1NHvQOoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{f1WWlEPTB;MD64N|I{OyEQvF2=NI[4emZUSU6JRWK=
LU-134-AM3\oeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnzWTWM2OD1yLkizPVEzKM7:TR?=MVHTRW5ITVJ?
SF268NXO5OnlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;k[2lEPTB;MD64OFA1OiEQvF2=NICx[HZUSU6JRWK=
KARPAS-45MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVL6OJN4UUN3ME2wMlg1OjZ|IN88US=>NIfD[Y1USU6JRWK=
TGWM2rIRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTBwOEW4OlMh|ryPMnzEV2FPT0WU
CHP-126MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnHWTWM2OD1yLki1PVU4KM7:TR?=NUPodYR3W0GQR1XS
MOLT-16M2LZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYPJR|UxRTBwOEe1PFkh|ryPM{W0[XNCVkeHUh?=
LB771-HNCM4jFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHzTWVhKSzVyPUCuPFk4PTdizszNNW\kXWxyW0GQR1XS
NALM-6NFLEeZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\Gd2lEPTB;MD65NFc{QSEQvF2=MlHEV2FPT0WU
GCIYNU\LfFVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIDh[JNKSzVyPUCuPVU2OjZizszNNH;5THpUSU6JRWK=
IST-MES1MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzMfXZ4UUN3ME2wMlk5QDJ2IN88US=>NH70WYtUSU6JRWK=
LB2241-RCCNXTNXFBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVj5S4p5UUN3ME2wMlk5QDRizszNMoLnV2FPT0WU
BL-70M4DC[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYTnWVJ[UUN3ME2wMlk6PTN3IN88US=>NV;Vd2R7W0GQR1XS
NB17MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfSTWM2OD1zLkCwOlM6KM7:TR?=MWnTRW5ITVJ?
LXF-289NV3nVVFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY\VeYtIUUN3ME2xMlA{ODd4IN88US=>NGO1RYhUSU6JRWK=
TK10MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mki1TWM2OD1zLkC1NFY{KM7:TR?=NV;ybm9PW0GQR1XS
K5NUPNNnVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jKcWlEPTB;MT6wOlI4PCEQvF2=MXjTRW5ITVJ?
NCI-H716MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\IVmlEPTB;MT6wO|I2QSEQvF2=M17V[nNCVkeHUh?=
HCE-TMlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYnIN21LUUN3ME2xMlA5QDF7IN88US=>MmLSV2FPT0WU
GI-1M4Dx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NILh[GxKSzVyPUGuNFk4QThizszNNF3nWY9USU6JRWK=
KARPAS-422NYK0bnFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHe2[GhKSzVyPUGuNVAxOjJizszNNU\qOmlRW0GQR1XS
TE-9MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTFwMUGzNlgh|ryPNXHLblZiW0GQR1XS
SF126MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnniTWM2OD1zLkGxOVY5KM7:TR?=NVXIW2JpW0GQR1XS
BB30-HNCM2i3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jjPGlEPTB;MT6xN|EyOiEQvF2=MXrTRW5ITVJ?
NCI-H1304MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTpTWM2OD1zLkGzN|M5KM7:TR?=MVPTRW5ITVJ?
HELMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYq2bWd7UUN3ME2xMlE1QDl3IN88US=>MnXLV2FPT0WU
HAL-01NFjTPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1n5W2lEPTB;MT6xOVI5OyEQvF2=NH;kXI9USU6JRWK=
SK-LMS-1M162XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mmn4TWM2OD1zLkG1PVc1KM7:TR?=MWTTRW5ITVJ?
SW954M3PFWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXDUI9KSzVyPUGuNVk2PjdizszNMVXTRW5ITVJ?
D-283MEDNFra[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEfqN4NKSzVyPUGuNlI{PzlizszNM2iwTnNCVkeHUh?=
NCI-H1882M3;KZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHQTZpMUUN3ME2xMlI{QDlizszNMk\CV2FPT0WU
GI-ME-NMmW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\BWppKSzVyPUGuNlUzODhizszNNHP2WIxUSU6JRWK=
SK-PN-DWM2nBUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH2ydFlKSzVyPUGuNlY{PDhizszNMX3TRW5ITVJ?
C2BBe1NVy5WoFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXvPSIJwUUN3ME2xMlI6OTF5IN88US=>MUPTRW5ITVJ?
A704NF3JOXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTFwM{K2PFkh|ryPMVXTRW5ITVJ?
KALS-1MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvNcHVPUUN3ME2xMlM1ODhizszNNVPufVNOW0GQR1XS
ETK-1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjpRZFKSzVyPUGuN|Q1QDlizszNNWiyXWN1W0GQR1XS
LB647-SCLCNF3SWZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEKxTmJKSzVyPUGuN|Q6QDZizszNNGH5S3JUSU6JRWK=
OCUB-MNFPtWpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NI\Be|lKSzVyPUGuN|YyPDNizszNMoP1V2FPT0WU
NCI-H720NVnSOYpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPvTWM2OD1zLkO2N|c5KM7:TR?=MWPTRW5ITVJ?
NB13MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTFwM{eyPVMh|ryPNWPPfWZIW0GQR1XS
GR-STMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX7JR|UxRTFwM{i3OVch|ryPNG\UbYZUSU6JRWK=
DU-4475NXXFXZVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mme5TWM2OD1zLkS1PFU{KM7:TR?=MX\TRW5ITVJ?
HCC2157NYX2fZA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVnXUJJ7UUN3ME2xMlQ3PjV7IN88US=>MmrUV2FPT0WU
RKOMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MofKTWM2OD1zLkS5PVIzKM7:TR?=NIXFNXVUSU6JRWK=
LS-123MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3foTGlEPTB;MT61NVU6PCEQvF2=NHryUnNUSU6JRWK=
NCI-H69MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;ybGlEPTB;MT61OVgyOSEQvF2=M1zRcXNCVkeHUh?=
SW962NIrWOWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmTWTWM2OD1zLkW2NVMh|ryPMlHHV2FPT0WU
PF-382MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlz5TWM2OD1zLkW2PVYh|ryPNV\mdWl5W0GQR1XS
A101DM1nkZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzRToRNUUN3ME2xMlU4OTF|IN88US=>NFLl[FlUSU6JRWK=
NB10NUPyN2ZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LSOGlEPTB;MT61O|M6OiEQvF2=NGXoO4xUSU6JRWK=
NB5NImzbJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4fFemlEPTB;MT61PFQ4PiEQvF2=M3LkcnNCVkeHUh?=
HCE-4NXXUc2JDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWSwcVF4UUN3ME2xMlYxQDVizszNNV3abJBiW0GQR1XS
HT-144MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV31WG9WUUN3ME2xMlY{OTlizszNNHnhNFhUSU6JRWK=
NCI-H524MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3HTWM2OD1zLk[0N|A4KM7:TR?=MWDTRW5ITVJ?
NKM-1MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTaTWM2OD1zLk[4OlYh|ryPMVjTRW5ITVJ?
KURAMOCHINWTQTpVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnvwTWM2OD1zLk[5OVc{KM7:TR?=NX7JfZZkW0GQR1XS
NCI-H187NGTDV|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYT6R4cxUUN3ME2xMlcxODN4IN88US=>NF\BSlVUSU6JRWK=
U-266M4DONGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYK0VWN1UUN3ME2xMlc{QDR{IN88US=>NWfHNYJmW0GQR1XS
BL-41MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIr0cotKSzVyPUGuO|YzPzJizszNMnH5V2FPT0WU
SK-N-DZMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGnidXlKSzVyPUGuO|g{ODlizszNNETuPG5USU6JRWK=
DaudiNVXCO3ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHMNXdKSzVyPUGuO|g6PjdizszNNWnTUJlsW0GQR1XS
CPC-NNHHKTpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmLuTWM2OD1zLki1NFk3KM7:TR?=M3PxbnNCVkeHUh?=
EM-2M3HzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlHoTWM2OD1zLki1NUDPxE1?MV\TRW5ITVJ?
HCC1187MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXJTWM2OD1zLki2NlQyKM7:TR?=NUXs[XAyW0GQR1XS
LP-1NWXtWItET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFX0R5RKSzVyPUGuPFcyPDNizszNMlHiV2FPT0WU
CAS-1MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTFwOUiyPVkh|ryPM2jMcnNCVkeHUh?=
NB7Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTJwMEC1OVUh|ryPM4LTSHNCVkeHUh?=
VA-ES-BJNX\YPZFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjjTWM2OD1{LkCxOVE{KM7:TR?=NHGweoZUSU6JRWK=
SNU-C2BNILqdndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4r3dGlEPTB;Mj6wN|M2OSEQvF2=MmjYV2FPT0WU
LOXIMVINUjNUY5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTJwME[3PFYh|ryPNVnFVGZtW0GQR1XS
NCI-H1581M4jqRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXURYNKSzVyPUKuNVE2PTlizszNNVjrR3ZHW0GQR1XS
IST-SL2NG\wW|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPyTWM2OD1{LkGyOFQ2KM7:TR?=MmrCV2FPT0WU
NOMO-1NYXmOod{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX3yOGdbUUN3ME2yMlE4Pjh|IN88US=>MUPTRW5ITVJ?
TE-6NGXVO3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFS3VppKSzVyPUKuNVkxPSEQvF2=NIjDZ4lUSU6JRWK=
NCI-H526NVLE[Jl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTJwMUmxOFEh|ryPMUPTRW5ITVJ?
MSTO-211HMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoryTWM2OD1{LkKwNFQyKM7:TR?=NHzVSY5USU6JRWK=
LS-513Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoH3TWM2OD1{LkKyNlY6KM7:TR?=NVHaXXJ1W0GQR1XS
NCI-SNU-1NUn6d4x2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mmi2TWM2OD1{LkOzNlU3KM7:TR?=MVrTRW5ITVJ?
BB65-RCCNIr3bXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPQTWM2OD1{LkO3OFk{KM7:TR?=MlSzV2FPT0WU
GT3TKBM3rw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTJwM{m5O|Ih|ryPMoSzV2FPT0WU
OS-RC-2M13rT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTpTWM2OD1{LkSyN|QyKM7:TR?=NF7GNG5USU6JRWK=
NCI-H2126M2XR[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGXPSGhKSzVyPUKuOFM3PzRizszNMmnYV2FPT0WU
SK-UT-1NYX2[|BXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTJwNEe0Olch|ryPM{LaOHNCVkeHUh?=
DMS-114MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlrkTWM2OD1{Lk[xOVI1KM7:TR?=MkHyV2FPT0WU
ONS-76NFrqPJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;KdGg1UUN3ME2yMlY{PjRzIN88US=>M{DVZXNCVkeHUh?=
8-MG-BAMoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrjO4FKSzVyPUKuOlU1OTRizszNNEfFTFVUSU6JRWK=
BOKUMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PPZ2lEPTB;Mj63Nlc3PCEQvF2=MkWyV2FPT0WU
LAMA-84MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn\6TWM2OD1{Lke5PVEzKM7:TR?=M1my[XNCVkeHUh?=
ES1Mmi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHzUOY9KSzVyPUKuPFE5ODRizszNMoTWV2FPT0WU
NCI-H1395MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIjJS2VKSzVyPUKuPFIxOTJizszNM2K1UXNCVkeHUh?=
A388NHHYSYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2TIdGlEPTB;Mj65OlE4KM7:TR?=NFjIVndUSU6JRWK=
NCCITNXTwRWpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HZWWlEPTB;Mz6wPFg3OiEQvF2=M2TiVHNCVkeHUh?=
HD-MY-ZMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmTNTWM2OD1|LkGzNlA{KM7:TR?=NGXET|VUSU6JRWK=
NCI-H510AM1PzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfwVoU3UUN3ME2zMlE5QTR|IN88US=>NWn2bGl5W0GQR1XS
NCI-N87NUG4enJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2fkVGlEPTB;Mz6yNFAzKM7:TR?=MofUV2FPT0WU
SCLC-21HMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTNwMk[4OVkh|ryPMkjuV2FPT0WU
SH-4NXXkXYdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnTZTWM2OD1|LkK4O|k4KM7:TR?=MkTBV2FPT0WU
QIMR-WILMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHTrS3ZKSzVyPUOuN|I5PDlizszNNHr0SZBUSU6JRWK=
KM12M2Trbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MULJR|UxRTNwM{O1OFQh|ryPM4Sw[HNCVkeHUh?=
ST486NXXpbWJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH3rUFNKSzVyPUOuOVM5QDNizszNMmm4V2FPT0WU
HC-1NVvjeG11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3jnSmlEPTB;Mz62NlAzQCEQvF2=NH7tSY1USU6JRWK=
BV-173MlrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXm4UGN1UUN3ME2zMlY1ODh6IN88US=>M4XkR3NCVkeHUh?=
EW-24NF\WfHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHLON4tKSzVyPUOuOlY1OzRizszNMUnTRW5ITVJ?
LU-65MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlfLTWM2OD1|Lk[4O|Eh|ryPMUPTRW5ITVJ?
ECC4NYXOTXk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEKybHJKSzVyPUOuO|c2PiEQvF2=Mn:0V2FPT0WU
ARH-77NX3tT5hST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHHhZ|JKSzVyPUSuNVExPjdizszNMWnTRW5ITVJ?
BC-3NIn5WpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWS2boNUUUN3ME20MlE{ODZ6IN88US=>MVvTRW5ITVJ?
SNB75M2H5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;peFBKSzVyPUSuNlYyQSEQvF2=Mn7oV2FPT0WU
MEG-01MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTRwMke0NVkh|ryPMV\TRW5ITVJ?
NCI-H1417MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{fqPGlEPTB;ND6yPFQ1OyEQvF2=MlTvV2FPT0WU
MDA-MB-134-VIMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFr0OZlKSzVyPUSuN|A3ODFizszNMkXnV2FPT0WU
BeckerMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXnISIw6UUN3ME20MlQ4OzN4IN88US=>MVHTRW5ITVJ?
DMS-153MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk\yTWM2OD12Lk[2OFc2KM7:TR?=NY\reZplW0GQR1XS
TGBC1TKBMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWS5fJVUUUN3ME20MlY5PTF3IN88US=>NV;5[W0yW0GQR1XS
EW-3NHi5VmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHiSmpQUUN3ME20Mlc3OjR6IN88US=>NVm1eXQ2W0GQR1XS
KE-37MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHj3dGpKSzVyPUSuPFYyQTZizszNMVjTRW5ITVJ?
NCI-H23NUS2NWJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTRwOEeyNlch|ryPM2TGOXNCVkeHUh?=
MC116NVz4XnBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;uT2lEPTB;ND65OFEzPiEQvF2=MXXTRW5ITVJ?
NH-12NVv2cZN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTRwOU[0N|kh|ryPMknVV2FPT0WU
CTB-1M{\iTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjUTWM2OD12Lkm3O|IyKM7:TR?=M1;ROnNCVkeHUh?=
KM-H2MoT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWnRfXBrUUN3ME21MlA2OzJ|IN88US=>M{\HZXNCVkeHUh?=
MOLT-4MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3IW|dxUUN3ME21MlEyQDNizszNMWLTRW5ITVJ?
NCI-H2141M1S1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1fyRWlEPTB;NT6xOFI3QCEQvF2=NIfzRZBUSU6JRWK=
EB-3NXjKeHMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlG2TWM2OD13LkG3OVA1KM7:TR?=NWH1fow6W0GQR1XS
NCI-H1522NVj1W|h[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk[5TWM2OD13LkK2N|IzKM7:TR?=MWXTRW5ITVJ?
MRK-nu-1M3Xifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnr5TWM2OD13LkSzOlM{KM7:TR?=MYrTRW5ITVJ?
no-11MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXRTWM2OD13LkS3NFg4KM7:TR?=NYPtTG5TW0GQR1XS
CESSMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnOTWM2OD13LkW4NFM1KM7:TR?=MUTTRW5ITVJ?
KMOE-2Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;hOWlEPTB;NT61PFY2QSEQvF2=MVrTRW5ITVJ?
REHM2jlV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnzMTWM2OD14LkK1OlE5KM7:TR?=MYLTRW5ITVJ?
KU812NXXUcm5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTZwNEK3PVEh|ryPNHnKWWVUSU6JRWK=
SK-N-FINF[5[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTZwNkC2O|Qh|ryPNFPIU4FUSU6JRWK=
MMAC-SFMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3nRVWlEPTB;Nz6wOlQ6OiEQvF2=MYHTRW5ITVJ?
RCC10RGBNVTrSpFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmDDTWM2OD15LkKyPVc4KM7:TR?=NHTHUphUSU6JRWK=
NCI-H322MNYPzSplOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M125b2lEPTB;Nz6zN|M{PSEQvF2=M1fpTXNCVkeHUh?=
NB6Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX7WWmtzUUN3ME23MlU1QDl7IN88US=>MWPTRW5ITVJ?
MN-60MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlLNTWM2OD15Lk[5NlE2KM7:TR?=M3nGWXNCVkeHUh?=
NCI-H1092NXnaPHJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrxd3p5UUN3ME24MlAyPzN2IN88US=>NW\pdmxLW0GQR1XS
EKVXNFrLVZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRThwNEewOlYh|ryPNYLjOIFbW0GQR1XS
D-263MGM3r4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rjWmlEPTB;OD61OVM6PiEQvF2=MWTTRW5ITVJ?
NCI-H209MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXSOYFKSzVyPUiuOlQxODZizszNMWrTRW5ITVJ?
IST-SL1NFzNRWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRThwOEm4PVIh|ryPM2XBc3NCVkeHUh?=
ACNNXLaN2dXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXrTWM2OD17LkG5NVU4KM7:TR?=MlHyV2FPT0WU
MHH-PREB-1M3i1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTlwMkGyNVkh|ryPMVHTRW5ITVJ?
EW-11M1PiWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2TjN2lEPTB;OT62OVM6PiEQvF2=M4m0XXNCVkeHUh?=
KASUMI-1M4rJTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4PIbGlEPTB;OT63PFc4KM7:TR?=Ml7KV2FPT0WU
KINGS-1M1mxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTFyLkKzOFch|ryPMmrGV2FPT0WU
EVSA-TMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1\vdmlEPTB;MUCuN|E6OiEQvF2=NEPiU3pUSU6JRWK=
DSH1M1\MT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIH3dZpKSzVyPUGwMlM6PzJizszNMnzrV2FPT0WU
COLO-824M336fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4O2OGlEPTB;MUCuPFY3QSEQvF2=NWf5UmNZW0GQR1XS
K052M1voW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfwSHJ6UUN3ME2xNE46OzJ{IN88US=>MlXjV2FPT0WU
SK-MEL-2Mn6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3vWUWlEPTB;MUCuPVk{QSEQvF2=M4WwdXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo After 4 weeks of treatment with TAE684 at 3 and 10 mg/kg, there is a significant delay in lymphoma development and 100- to 1,000-fold reduction in luminescence signal, without any signs of compound- or disease-related toxicity in Karpas-299 lymphoma model. TAE684 treatment also induces disease regression in established Karpas-299 lymphomas and down-regulates CD30 expression. [1] TAE684 also shows impressive antitumor activity against H3122 CR xenograft tumors. [2] Furthermore, treatment with TAE684 improves the rough eye phenotype of both ALK mutants, especially that seen with ALKR1275Q, whereas Crizotinib has little effect on either phenotype. [3]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

In vitro Enzyme Assays. All in vitro enzyme assays are done at Upstate Biotechnology with the exception of InsR and IGF-1R. To determine the IC50 of TAE684 against InsR and IGF-1R a homogeneous time-resolved fluorescence assay is performed. ATP (10 mM) and 20 mg/ml biotinylated PolyEY (Glu, Tyr 4:1) are combined with 50 nL of serial dilutions of TAE684 (10-500 nM) and 4 ng of InsR enzyme in the presence of the kinase reaction buffer (20 mM Tris譎Cl, pH 7.5/10 mM MgCl2/3 mM MnCl2/1 mM DTT/10 mM NaVO4/0.1 mg/ml of BSA). Assays are incubated for 1 hour at ambient temperature. Reactions are terminated by adding 10 mL of the detection solution containing 50 mM EDTA, 500 mM KF, 0.5 mg/ml of BSA, 5 mg/mL Eu3+ cryptate-labeled anti-phosphotyrosine antibody Mab PT66-K, and 5 mg/mL Streptavidin-XLent. The reaction is incubated for half an hour, and fluorescence signals are read on Analyst GT.

Cell Assay: [1]

Cell lines Luciferase-expressing Karpas-299, SU-DHL-1, and Ba/F3 cells and transformed Ba/F3 stably expressing NPM-ALK, Bcr-Abl, or TEL-kinase fusion constructs.
Concentrations 1 nM-10 μM
Incubation Time 2–3 days
Method Cells are seeded in 384-well plates (2.5×104 cells per well) and incubated with serial dilutions of TAE684 or DMSO for 2–3 days. Luciferase expression is used as a measure of cell proliferation/survival and is evaluated with the Bright-Glo Luciferase Assay System. IC50 values are generated by using XLFit software.

Animal Study: [1]

Animal Models Karpas-299 xenografts are established in 4- to 6-week old female Fox Chase SCIDBeige mice.
Formulation Resuspended in 10% 1-methyl-2-pyrrolidinone/90% polyethylene glycol 300 solution
Dosages 1, 3, and 10 mg/kg
Administration Once daily by oral gavage for 3 weeks

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Galkin AV, et al. Proc Natl Acad Sci U S A, 2007, 104(1), 270-275.

[2] Katayama R, et al. Proc Natl Acad Sci U S A, 2011, 108(18), 7535-7540.

view more

Chemical Information

Download TAE684 (NVP-TAE684) SDF
Molecular Weight (MW) 614.2
Formula

C30H40ClN7O3S

CAS No. 761439-42-3
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 3 mg/mL (4.88 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% PEG400/0.5% Tween80/5% propylene glycol, pH 4 10 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine

Customer Product Validation (4)


Click to enlarge
Rating
Source Cancer Res 2011 71, 4920-31. TAE684 (NVP-TAE684) purchased from Selleck
Method Western blot
Cell Lines H3122 cells
Concentrations 100 nmol/L
Incubation Time 6 h
Results Figure A shows that the primary adaptors for PI3K activation are IRS1 and IRS2 in H3122 mouse xenografts. Interestingly, treatment with TAE-684 eliminates these interactions, suggesting that ALK signals to PI3K via IRS2 and IRS1. This is consistent with previous reports suggesting that NPM-ALK signals to PI3K via IRS proteins. The finding that IRS proteins were utilized to activate PI3K suggested that these cells might activate PI3K in response to IGF-I. Indeed, treatment of H3122 cells with IGF-I, but not EGF or HGF, rescued PI3K-AKT signaling with TAE-684 treatment (Fig. B).

Click to enlarge
Rating
Source Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck
Method Western blot
Cell Lines H-1299 cells
Concentrations 0.03-1uM
Incubation Time
Results Treatment efficiently inhibited the cell proliferation and phospho-Y1604 ALK expression of H694R or E1384K mutant ALK, but also to a degree higher than that of wild-type ALK.

Click to enlarge
Rating
Source Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck
Method Xenograft
Cell Lines mice
Concentrations
Incubation Time 4 weeks
Results Consistently, TAE684 treatment repressed H694R- and E1384K-induced tumor growth compared with DMSO control.

Click to enlarge
Rating
Source Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck
Method Cell Proliferation Assay
Cell Lines H-1299 cells
Concentrations 0-3 uM
Incubation Time
Results Treatment efficiently inhibited the cell proliferation and phospho- Y1604 ALK expression of H694R or E1384K mutant ALK, but also to a degree higher than that of wild-type ALK.

Product Use Citation (17)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related ALK Products

  • PF-06463922

    PF-06463922 is a potent, dual ALK/ROS1 inhibitor with Ki of <0.02 nM, <0.07 nM, and 0.7 nM for ROS1, ALK (WT), and ALK (L1196M), respectively. Phase 1.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • R428 (BGB324)

    R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).

  • GSK1838705A

    GSK1838705A is a potent IGF-1R inhibitor with IC50 of 2.0 nM, modestly potent to IR and ALK with IC50 of 1.6 nM and 0.5 nM, respectively, and little activity to other protein kinases.

    Features:A small-molecule kinase inhibitor of IGF-1R and the insulin receptor.

  • Alectinib (CH5424802)

    Alectinib (CH5424802) is a potent ALK inhibitor with IC50 of 1.9 nM in cell-free assays, sensitive to L1196M mutation and higher selectivity for ALK than PF-02341066, NVP-TAE684 and PHA-E429.

  • AP26113

    AP26113 is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay, demonstrated ability overcome Crizotinib resistance mediated by a L1196M mutation. Phase 2.

    Features:At least 10-fold more potent and selective in ALK inhibition relative to crizotinib.

  • ASP3026

    ASP3026 is a novel and selective inhibitor for ALK with IC50 of 3.5 nM. Phase 1.

  • AZD3463

    AZD3463 is a novel orally bioavailable ALK inhibitor with Ki of 0.75 nM, which also inhibits IGF1R with equivalent potency.

  • Ceritinib (LDK378)

    Ceritinib (LDK378) is potent inhibitor against ALK with IC50 of 0.2 nM in cell-free assays, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively. Phase 3.

    Features:Does not cross react with c-Met, and has an improved in vivo glucose homeostasis profile relative to TAE684. May be active in Crizotinib-relapsed tumors.

  • Gefitinib (ZD1839)

    Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

    Features:A potent EGFR tyrosine kinase inhibitor.

Recently Viewed Items

Tags: buy TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) supplier | purchase TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) cost | TAE684 (NVP-TAE684) manufacturer | order TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us